Analysts think VKTX stock price could increase by 242%
Jul 09, 2025, 11:25 AM
8.29%
What does VKTX do
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
19 analysts think VKTX stock price will increase by 241.58%. The current median analyst target is $103.02 compared to a current stock price of $30.16. The lowest analysts target is $30.30 and the highest analyst target is $131.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
